Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome.
OBJECTIVE
To characterize the difference in circulating anti-Müllerian hormone (AMH) levels between the main polycystic ovary syndrome (PCOS) phenotypic groups and evaluate the role of AMH in predicting the severity of PCOS.


STUDY DESIGN
Cross-sectional, retrospective study. A total of 251 women were divided into four groups based on the main features of PCOS, as follows: Group 1 (polycystic ovarian morphology [PCOM]+/oligo-anovulation [OA]+/hyperandrogenism [HA]+), Group 2 (PCOM+/OA+/HA-), Group 3 (PCOM+/OA-/HA+), and Group 4 (PCOM-/OA+/HA+). AMH and other hormone levels were measured in serum. The main outcome was serum AMH concentrations in the main phenotypes of PCOS.


RESULT(S)
The mean serum AMH levels were 9.50±6.1 ng/mL in Group 1; 8.02±6.2 ng/mL in Group 2; 6.12±3.6 ng/mL in Group 3; and 3.06±2.4 ng/mL in Group 4. Circulating AMH levels in Group 1 (PCOM+/OA+/HA+) were three times higher than those in Group 4 (PCOM-/OA+/HA+).


CONCLUSIONS
The highest AMH levels were found in cases where all three main diagnostic criteria existed. AMH levels correlate best with PCOM. In addition, oligo-anovulation contributes to increased AMH levels. Hyperandrogenism criteria were found to have less influence on AMH levels. AMH levels seem to have a diagnostic role in determining the severity of PCOS.
['Sahmay|Sezai|S|', 'Atakul|Nil|N|', 'Oncul|Mahmut|M|', 'Tuten|Abdullah|A|', 'Aydogan|Begum|B|', 'Seyisoglu|Hakan|H|']
D000328:Adult D000858:Anovulation D054304:Anti-Mullerian Hormone D015415:Biomarkers D003430:Cross-Sectional Studies D005260:Female D006801:Humans D017588:Hyperandrogenism D010053:Ovary D010641:Phenotype D011085:Polycystic Ovary Syndrome D012189:Retrospective Studies D055815:Young Adult
AMH Hyperandrogenism Polycystic ovarian syndrome